Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27148465 | 0.84 | CKS1B (0.49) | L3MBTL1KMT2A | |
| SCHEMBL30851816 | 0.82 | CCNE1 (0.50) | ALDH1A1CCNE1CDK2POLBRAB9A | |
| SCHEMBL20140934 | 0.82 | ALDH1A1 (0.48) | L3MBTL1SIGMAR1ALDH1A1C5AR1 | |
| SCHEMBL30852024 | 0.79 | PIK3CD (0.48) | CCNE1CDK2 | |
| SCHEMBL30852044 | 0.79 | KMT2A (0.48) | L3MBTL1ALDH1A1CCNE1CDK2POLB | |
| SCHEMBL27307706 | 0.77 | SLC6A2 (0.42) | ALDH1A1FFAR1POLBC5AR1KMT2A | |
| SCHEMBL30852175 | 0.76 | FFAR1 (0.44) | FFAR1C5AR1 | |
| SCHEMBL28703207 | 0.76 | SSTR2 (0.43) | ALDH1A1POLBC5AR1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL30852171 | 0.75 | SSTR2 (0.42) | ALDH1A1POLBC5AR1KMT2AMEN1 | |
| SCHEMBL23573437 | 0.74 | L3MBTL1 (0.52) | L3MBTL1CDK2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | US | disclosed |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-03-21 | — | — | US | disclosed |
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | L3MBTL1 4871/4885SIGMAR1 1141/4885ALDH1A1 2010/4885 |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | L3MBTL1 4871/4885SIGMAR1 1141/4885ALDH1A1 2010/4885 |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | C5AR1, C3AR1, C5AR2 | L3MBTL1 4822/4885SIGMAR1 887/4885ALDH1A1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.